Technical Analysis for IOVA - Iovance Biotherapeutics, Inc.

Grade Last Price % Change Price Change
grade D 23.74 0.25% 0.06
IOVA closed up 0.25 percent on Thursday, January 16, 2020, on 67 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong Up Down Down
Historical IOVA trend table...

Date Alert Name Type % Chg
Calm After Storm Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Oversold Stochastic Weakness 0.00%
MACD Bearish Centerline Cross Bearish 0.25%
Calm After Storm Range Contraction 0.25%
Lower Bollinger Band Walk Weakness 0.25%
Stochastic Reached Oversold Weakness 0.25%
Inside Day Range Contraction 0.25%

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Iovance Biotherapeutics, Inc., formerly Lion Biotechnologies, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient's own immune system to eradicate cancer cells. The Company's lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients' tumors, for the treatment of metastatic melanoma. As of December 31, 2016, it had an on-going Phase II clinical trial of its lead product candidate, LN-144, TIL for the treatment of metastatic melanoma. The Company is developing LN-145 to treat cervical and head and neck cancers. It is collaborating with the National Cancer Institute to evaluate unmodified TIL in other solid tumor indications, such as ocular melanoma, bladder, breast and lung cancer. It is collaborating with the NCI to evaluate TIL in combination with the checkpoint inhibitor, Keytruda.
Medicine Biopharmaceutical Cancer Clinical Medicine Immunotherapy Oncology Cancer Treatments Cancer Immunotherapy Antineoplastic Drugs Melanoma Cell Therapy Solid Tumor Metastatic Melanoma Adoptive Cell Transfer Cancer Immunotherapy Products Head And Neck Cancers Breast And Lung Cancer National Cancer Institute Ocular Melanoma Treatment Of Metastatic Melanoma

Is IOVA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 29.67
52 Week Low 8.26
Average Volume 1,327,444
200-Day Moving Average 20.41
50-Day Moving Average 24.94
20-Day Moving Average 26.89
10-Day Moving Average 25.51
Average True Range 1.37
ADX 28.9
+DI 16.97
-DI 29.94
Chandelier Exit (Long, 3 ATRs ) 25.57
Chandelier Exit (Short, 3 ATRs ) 27.25
Upper Bollinger Band 30.54
Lower Bollinger Band 23.24
Percent B (%b) 0.07
BandWidth 27.12
MACD Line -0.26
MACD Signal Line 0.33
MACD Histogram -0.5963
Fundamentals Value
Market Cap 1.7 Billion
Num Shares 71.5 Million
EPS -2.08
Price-to-Earnings (P/E) Ratio -11.41
Price-to-Sales 0.00
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 24.76
Resistance 3 (R3) 24.73 24.36 24.59
Resistance 2 (R2) 24.36 24.09 24.37 24.54
Resistance 1 (R1) 24.05 23.93 24.20 24.08 24.48
Pivot Point 23.67 23.67 23.75 23.69 23.67
Support 1 (S1) 23.36 23.41 23.52 23.40 23.00
Support 2 (S2) 22.99 23.25 23.01 22.94
Support 3 (S3) 22.68 22.99 22.89
Support 4 (S4) 22.72